alendronate has been researched along with Mandibular Diseases in 47 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Mandibular Diseases: Diseases involving the MANDIBLE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to evaluate a possible role of microcracks in the pathogenesis of bisphosphonate-related osteonecrosis of the jaw (ONJ) and to discuss an etiological model." | 7.76 | Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. ( Eufinger, H; Hoefert, S; Schmitz, I; Tannapfel, A, 2010) |
| "We report a case of diffuse sclerosing osteomyelitis of the mandible responded to alendronate, after a poor response to intravenous antibiotics, antibiotic irrigation-perfusion, and decortication." | 7.73 | Response of diffuse sclerosing osteomyelitis of the mandible to alendronate: follow-up study by 99mTc scintigraphy. ( Hamakawa, H; Hino, S; Murase, R; Shintani, S; Terakado, N, 2005) |
| "This study tested the efficacy of alendronate, a bisphosphate, in reducing alveolar bone loss caused by experimental periodontitis in cynomolgus monkeys." | 7.69 | Histomorphometrical analysis of the effects of the bisphosphonate alendronate on bone loss caused by experimental periodontitis in monkeys. ( Aufdemorte, TB; Brunsvold, M; Chaves, E; Kornman, KS; Quartuccio, H; Rodan, GA; Seedor, JG; Weinreb, M, 1994) |
| "We have found 11 cases of BRONJ in our hospital: 4 women taking oral alendronate or risendronate for osteoporosis and 7 cancer patients treated with intravenous zolendronic acid." | 4.88 | [Bisphosphonate related osteonecrosis of the jaw and infection with Actinomyces]. ( Arranz Caso, JA; Dominguez-Mompello, JL; Flores Ballester, E; López Pizarro, V; Ngo Pombe, S; Restoy Lozano, A, 2012) |
| "The aim of this study was to evaluate a possible role of microcracks in the pathogenesis of bisphosphonate-related osteonecrosis of the jaw (ONJ) and to discuss an etiological model." | 3.76 | Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. ( Eufinger, H; Hoefert, S; Schmitz, I; Tannapfel, A, 2010) |
| "We report a case of diffuse sclerosing osteomyelitis of the mandible responded to alendronate, after a poor response to intravenous antibiotics, antibiotic irrigation-perfusion, and decortication." | 3.73 | Response of diffuse sclerosing osteomyelitis of the mandible to alendronate: follow-up study by 99mTc scintigraphy. ( Hamakawa, H; Hino, S; Murase, R; Shintani, S; Terakado, N, 2005) |
| "This study tested the efficacy of alendronate, a bisphosphate, in reducing alveolar bone loss caused by experimental periodontitis in cynomolgus monkeys." | 3.69 | Histomorphometrical analysis of the effects of the bisphosphonate alendronate on bone loss caused by experimental periodontitis in monkeys. ( Aufdemorte, TB; Brunsvold, M; Chaves, E; Kornman, KS; Quartuccio, H; Rodan, GA; Seedor, JG; Weinreb, M, 1994) |
| "Periodontal disease is characterized by periodontal bone loss." | 2.73 | Efficacy of bisphosphonates for the control of alveolar bone loss in periodontitis. ( Cizza, G; Genco, R; Jeffcoat, MK; Lombardi, A; Shih, WJ, 2007) |
| "Because the severity of alveolar bone loss increases with age, it has long been hypothesized that it may, in part, be related to systemic conditions that also predispose the patient to osteoporosis/osteopenia." | 2.40 | Osteoporosis: a possible modifying factor in oral bone loss. ( Jeffcoat, MK, 1998) |
| "We obtained complete control of neuropathic pain after 6 months of the patients' evolution, preserving the function of the lingual nerve in all 3 neurolysis, without causing any impact as regards to the sensitive situation before treatment." | 1.40 | Surgical neurolysis for the treatment of neuropathic pain in 2 postmenopausal women with mandibular necrosis resulting from oral bisphosphonates. ( Gandara-Rey, JM; Garcia-Garcia, A; Perez-Sayans, M; Somoza-Martin, M, 2014) |
| "Alendronate was the most frequently implicated (six cases) and risedronate (five cases)." | 1.36 | [Jaw osteonecrosis induced by oral biphosphonates: 12 cases]. ( Barrier, A; Descroix, V; Goudot, P; Lescaille, G; Rigolet, A; Ruhin, B, 2010) |
| " Current reports have focused on therapy-resistant osteonecrosis of the jaws as a possible side effect of bisphosphonates." | 1.33 | [Osteonecrosis of the jaws as a possible adverse effect of the use of bisphosphonates]. ( Eufinger, H; Hoefert, S, 2005) |
| "Here we report 29 cases of bone necrosis of the jaws in patients treated with pamidronate (Aredia), zoledronate (Zometa) and alendronate: 15 underwent surgical procedures and 14 occurred spontaneously." | 1.33 | Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases. ( Bonaninil, M; Corcione, L; Corradi, D; D'Aleo, P; Ferrari, S; Guidotti, R; Manfredi, M; Meleti, M; Merigo, E; Poli, T; Ripasarti, A; Sesenna, E; Vescovi, P; Zanzucchi, E, 2006) |
| "The alendronate or saline was administered subcutaneously 1 week prior to surgery, immediately prior to surgery, and 1 week after surgery." | 1.32 | A histopathological investigation on the effect of systemic administration of the bisphosphonate alendronate on resorptive phase following mucoperiosteal flap surgery in the rat mandible. ( Bostanci, H; Günhan, O; Kaynak, D; Meffert, R; Ozkaya, OG, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (6.38) | 18.2507 |
| 2000's | 21 (44.68) | 29.6817 |
| 2010's | 23 (48.94) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| López-Cedrún, JL | 1 |
| Sanromán, JF | 1 |
| García, A | 1 |
| Peñarrocha, M | 1 |
| Feijoo, JF | 1 |
| Limeres, J | 1 |
| Diz, P | 1 |
| Prada García, C | 1 |
| Rodríguez Prieto, MÁ | 1 |
| Ulmner, M | 1 |
| Jarnbring, F | 1 |
| Törring, O | 1 |
| Zaman, MU | 1 |
| Nakamoto, T | 1 |
| Tanimoto, K | 1 |
| Hamada, H | 1 |
| Matsuo, A | 1 |
| Koizumi, T | 1 |
| Satomi, T | 1 |
| Chikazu, D | 1 |
| Kaehling, Ch | 1 |
| Streckbein, P | 1 |
| Schmermund, D | 1 |
| Henrich, M | 1 |
| Burchert, D | 1 |
| Gattenloehner, S | 1 |
| Howaldt, HP | 1 |
| Wilbrand, JF | 1 |
| Garcia-Garcia, A | 1 |
| Somoza-Martin, M | 1 |
| Gandara-Rey, JM | 1 |
| Perez-Sayans, M | 1 |
| Ribeiro, NR | 1 |
| Silva, Lde F | 1 |
| Santana, DM | 1 |
| Nogueira, RL | 1 |
| Pham Dang, N | 1 |
| Longeac, M | 1 |
| Picard, M | 1 |
| Devoize, L | 1 |
| Barthélémy, I | 1 |
| Lehrer, S | 1 |
| Montazem, A | 1 |
| Ramanathan, L | 1 |
| Pessin-Minsley, M | 1 |
| Pfail, J | 1 |
| Stock, RG | 1 |
| Kogan, R | 1 |
| Kwon, YD | 1 |
| Kim, YR | 1 |
| Choi, BJ | 1 |
| Lee, DW | 1 |
| Kim, DY | 1 |
| Wongchuensoontorn, C | 1 |
| Liebehenschel, N | 1 |
| Wagner, K | 1 |
| Fakler, O | 1 |
| Gutwald, R | 1 |
| Schmelzeisen, R | 2 |
| Sauerbier, S | 2 |
| Hoefert, S | 2 |
| Schmitz, I | 1 |
| Tannapfel, A | 1 |
| Eufinger, H | 2 |
| Burr, DB | 2 |
| Allen, MR | 2 |
| Treister, NS | 1 |
| Friedland, B | 1 |
| Woo, SB | 1 |
| Chiu, CT | 1 |
| Chiang, WF | 1 |
| Chuang, CY | 1 |
| Chang, SW | 1 |
| Kuijpers, SC | 1 |
| van Roessel, EW | 1 |
| van Merkesteyn, JP | 1 |
| Ezzat, BA | 1 |
| Barrier, A | 1 |
| Lescaille, G | 1 |
| Rigolet, A | 1 |
| Descroix, V | 1 |
| Goudot, P | 1 |
| Ruhin, B | 1 |
| Alloh Amichia, YC | 1 |
| Le Bars, P | 1 |
| Giumelli, B | 1 |
| Soueidan, A | 1 |
| Fitzpatrick, SG | 1 |
| Stavropoulos, MF | 1 |
| Bowers, LM | 1 |
| Neuman, AN | 1 |
| Hinkson, DW | 1 |
| Green, JG | 1 |
| Bhattacharyya, I | 1 |
| Cohen, DM | 1 |
| Zadik, Y | 1 |
| Benoliel, R | 1 |
| Fleissig, Y | 1 |
| Casap, N | 1 |
| Voss, PJ | 1 |
| Joshi Oshero, J | 1 |
| Kovalova-Müller, A | 1 |
| Veigel Merino, EA | 1 |
| Al-Jamali, J | 1 |
| Lemound, J | 1 |
| Metzger, MC | 1 |
| Ghazali, N | 1 |
| Collyer, JC | 1 |
| Tighe, JV | 1 |
| Scully, C | 1 |
| Brooke, AE | 1 |
| Arranz Caso, JA | 1 |
| Flores Ballester, E | 1 |
| Ngo Pombe, S | 1 |
| López Pizarro, V | 1 |
| Dominguez-Mompello, JL | 1 |
| Restoy Lozano, A | 1 |
| Ohbayashi, Y | 1 |
| Miyake, M | 1 |
| Sawai, F | 1 |
| Minami, Y | 1 |
| Iwasaki, A | 1 |
| Matsui, Y | 1 |
| Kaynak, D | 1 |
| Meffert, R | 1 |
| Bostanci, H | 1 |
| Günhan, O | 1 |
| Ozkaya, OG | 1 |
| Chun, CS | 1 |
| Carter, G | 1 |
| Goss, AN | 1 |
| Doecke, C | 1 |
| Hino, S | 1 |
| Murase, R | 1 |
| Terakado, N | 1 |
| Shintani, S | 1 |
| Hamakawa, H | 1 |
| Marunick, M | 1 |
| Gordon, S | 1 |
| Nase, JB | 1 |
| Suzuki, JB | 1 |
| Talbi, M | 1 |
| Carrie, F | 1 |
| Meley, M | 1 |
| Merigo, E | 1 |
| Manfredi, M | 1 |
| Meleti, M | 1 |
| Guidotti, R | 1 |
| Ripasarti, A | 1 |
| Zanzucchi, E | 1 |
| D'Aleo, P | 1 |
| Corradi, D | 1 |
| Corcione, L | 1 |
| Sesenna, E | 1 |
| Ferrari, S | 1 |
| Poli, T | 1 |
| Bonaninil, M | 1 |
| Vescovi, P | 1 |
| Robb-Nicholson, C | 1 |
| Harper, RP | 1 |
| Fung, E | 1 |
| Letonturier, P | 1 |
| Jeffcoat, MK | 3 |
| Cizza, G | 1 |
| Shih, WJ | 1 |
| Genco, R | 1 |
| Lombardi, A | 1 |
| Udvardy, E | 1 |
| Redl, P | 1 |
| Márton, I | 1 |
| Weinreb, M | 1 |
| Quartuccio, H | 1 |
| Seedor, JG | 1 |
| Aufdemorte, TB | 1 |
| Brunsvold, M | 1 |
| Chaves, E | 1 |
| Kornman, KS | 1 |
| Rodan, GA | 1 |
| Yaffe, A | 1 |
| Iztkovich, M | 1 |
| Earon, Y | 1 |
| Alt, I | 1 |
| Lilov, R | 1 |
| Binderman, I | 1 |
| Lewis, CE | 1 |
| Reddy, MS | 1 |
| Wang, CY | 1 |
| Redford, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Orally Administered Bisphosphonates in the Treatment of Osteoporosis on the Alveolar Bone Using Panoramic and Cone-Beam CT Imaging: A Case-control Study[NCT02115490] | 60 participants (Actual) | Observational | 2014-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for alendronate and Mandibular Diseases
| Article | Year |
|---|---|
[Central giant cell granuloma in children: Presentation of different therapeutic options].
Topics: Alendronate; Calcitonin; Child; Denosumab; Glucocorticoids; Granuloma, Giant Cell; Humans; Interfero | 2016 |
[Bisphosphonate related osteonecrosis of the jaw and infection with Actinomyces].
Topics: Actinomyces; Actinomycosis; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Bisphosphon | 2012 |
Chronic recurrent multifocal osteomyelitis of the spine and mandible: case report and review of the literature.
Topics: Alendronate; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Child, Preschool; Chron | 2004 |
[Osteonecrosis of the jaw developing during bisphosphonate treatment].
Topics: Alendronate; Anti-Infective Agents; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodelin | 2008 |
Osteoporosis: a possible modifying factor in oral bone loss.
Topics: Alendronate; Alveolar Bone Loss; Bone Density; Estrogen Replacement Therapy; Female; Humans; Male; M | 1998 |
Post-menopausal bone loss and its relationship to oral bone loss.
Topics: Absorptiometry, Photon; Alendronate; Alveolar Bone Loss; Bone Density; Calcium; Estrogen Replacement | 2000 |
1 trial available for alendronate and Mandibular Diseases
| Article | Year |
|---|---|
Efficacy of bisphosphonates for the control of alveolar bone loss in periodontitis.
Topics: Adult; Aged; Alendronate; Alveolar Bone Loss; Alveolar Process; Analysis of Variance; Bone Density; | 2007 |
40 other studies available for alendronate and Mandibular Diseases
| Article | Year |
|---|---|
Oral bisphosphonate-related osteonecrosis of the jaws in dental implant patients: a case series.
Topics: Administration, Oral; Adrenal Cortex Hormones; Aged; Alendronate; Bisphosphonate-Associated Osteonec | 2013 |
Submandibular cutaneous fistula.
Topics: Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Con | 2013 |
Osteonecrosis of the jaw in Sweden associated with the oral use of bisphosphonate.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Alendronate; Bisphosphonate-Associated O | 2014 |
A retrospective study of digital subtraction technique to detect sclerotic changes in alveolar bone on intraoral radiographs of bisphosphonate-treated patients.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Alveolar Process; Anatomic Landmarks; Bisphosphonate-As | 2013 |
A simple evaluation method for early detection of bisphosphonate-related osteonecrosis of the mandible using computed tomography.
Topics: Administration, Intravenous; Administration, Oral; Alendronate; Alveolar Process; Bisphosphonate-Ass | 2014 |
Lethal cervical abscess following bisphosphonate related osteonecrosis of the jaw.
Topics: Abscess; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation | 2014 |
Surgical neurolysis for the treatment of neuropathic pain in 2 postmenopausal women with mandibular necrosis resulting from oral bisphosphonates.
Topics: Aged; Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Cranial Ne | 2014 |
Bisphosphonate-Related Osteonecrosis of the Jaw After Tooth Extraction.
Topics: Administration, Oral; Aged; Alendronate; Anti-Bacterial Agents; Anti-Infective Agents, Local; Bispho | 2015 |
Bisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate gene.
Topics: Alendronate; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Collagen Type I; Cysteine | 2009 |
Oral bisphosphonate-related osteonecrosis of the jaws: favorable outcome after bisphosphonate holiday.
Topics: Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; Collagen Type I; Drug Adm | 2009 |
Pathological fractures in patients caused by bisphosphonate-related osteonecrosis of the jaws: report of 3 cases.
Topics: Administration, Oral; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonat | 2009 |
Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Connective Tissue; Di | 2010 |
Mandibular necrosis in beagle dogs treated with bisphosphonates.
Topics: Alendronate; Alveolar Process; Animals; Bone Density Conservation Agents; Bone Matrix; Bone Remodeli | 2009 |
Use of cone-beam computerized tomography for evaluation of bisphosphonate-associated osteonecrosis of the jaws.
Topics: Adult; Aged; Alendronate; Bone Density Conservation Agents; Cone-Beam Computed Tomography; Diphospho | 2010 |
Resolution of oral bisphosphonate and steroid-related osteonecrosis of the jaw--a serial case analysis.
Topics: Actinomycosis; Administration, Oral; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Bo | 2010 |
Unusual case of a conservatively treated pathological fracture after sequestrectomy in a patient with long-term oral bisphosphonate use.
Topics: Administration, Oral; Aged; Alendronate; Anti-Bacterial Agents; Bone Density Conservation Agents; Di | 2011 |
Validity of prevention of glucocorticoid-induced alveolar bone loss in rat by either calcitonin or alendronate administration.
Topics: Alendronate; Alveolar Bone Loss; Animals; Bone Density; Bone Density Conservation Agents; Calcitonin | 2010 |
[Jaw osteonecrosis induced by oral biphosphonates: 12 cases].
Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Alendronate; Autoimmu | 2010 |
[Prosthetic rehabilitation after osteonecrosis of the jaws due to histiocytosis X and treatment with bisphosphonates apropos of a case].
Topics: Adult; Alendronate; Bone Density Conservation Agents; Denture Design; Denture, Partial, Fixed; Dentu | 2010 |
Bisphosphonate-related osteonecrosis of jaws in 3 osteoporotic patients with history of oral bisphosphonate use treated with single yearly zoledronic acid infusion.
Topics: Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Age | 2012 |
Painful trigeminal neuropathy induced by oral bisphosphonate-related osteonecrosis of the jaw: a new etiology for the numb-chin syndrome.
Topics: Aged; Alendronate; Amitriptyline; Analgesics, Non-Narcotic; Bisphosphonate-Associated Osteonecrosis | 2012 |
Surgical treatment of bisphosphonate-associated osteonecrosis of the jaw: technical report and follow up of 21 patients.
Topics: Aged; Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Densi | 2012 |
Hemimandibulectomy and vascularized fibula flap in bisphosphonate-induced mandibular osteonecrosis with polycythaemia rubra vera.
Topics: Aged, 80 and over; Alendronate; Aspirin; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone De | 2013 |
Images in clinical medicine. Halitosis and sensory loss.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Female; Halitosis; Humans; Mandibular Diseases; | 2012 |
Adjunct teriparatide therapy with monitoring of bone turnover markers and bone scintigraphy for bisphosphonate-related osteonecrosis of the jaw.
Topics: Acid Phosphatase; Aged; Alendronate; Alkaline Phosphatase; Amino Acids; Biomarkers; Bisphosphonate-A | 2013 |
A histopathological investigation on the effect of systemic administration of the bisphosphonate alendronate on resorptive phase following mucoperiosteal flap surgery in the rat mandible.
Topics: Alendronate; Alveolar Bone Loss; Alveolar Process; Animals; Bone Resorption; Chi-Square Distribution | 2003 |
Bisphosphonates and avascular necrosis of the jaw: a possible association.
Topics: Aged; Aged, 80 and over; Alendronate; Anti-Inflammatory Agents; Diphosphonates; Female; Follow-Up St | 2005 |
Response of diffuse sclerosing osteomyelitis of the mandible to alendronate: follow-up study by 99mTc scintigraphy.
Topics: Adult; Alendronate; Facial Pain; Follow-Up Studies; Humans; Infusions, Intravenous; Mandible; Mandib | 2005 |
[Osteonecrosis of the jaws as a possible adverse effect of the use of bisphosphonates].
Topics: Aged; Alendronate; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Male; Mandibular D | 2005 |
Prosthodontic treatment during active osteonecrosis related to radiation and bisphosphonate therapy: a clinical report.
Topics: Alendronate; Bone Density Conservation Agents; Carcinoma, Squamous Cell; Cranial Irradiation; Dentur | 2006 |
Osteonecrosis of the jaw and oral bisphosphonate treatment.
Topics: Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; Debridement; Dental Carie | 2006 |
[Bisphosphonate-related bilateral mandibular osteochemonecrosis with pathological fracture of the horizontal ramus].
Topics: Aged; Alendronate; Bone Density Conservation Agents; Fractures, Spontaneous; Humans; Male; Mandibula | 2006 |
Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases.
Topics: Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Antifungal Agents; Bone Density Conserv | 2006 |
By the way, doctor. I'm 60 and have osteoporosis. My doctor is recommending Fosamax, but I'm concerned about jawbone problems. Are there any other drugs I can take?
Topics: Alendronate; Bone Density Conservation Agents; Estrogen Replacement Therapy; Exercise; Female; Human | 2006 |
Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)].
Topics: Aged; Alendronate; Bone Density Conservation Agents; Clinical Protocols; Female; Humans; Injections, | 2007 |
[Questions and answers about bisphosphonates].
Topics: Administration, Oral; Age Factors; Alendronate; Bone Density; Bone Density Conservation Agents; Bone | 2007 |
Bisphosphonates. A cornerstone of osteoporosis treatment.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Estrogen Replacement Therapy; Etidron | 2007 |
Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment.
Topics: Administration, Oral; Alendronate; Analysis of Variance; Animals; Bone Density Conservation Agents; | 2008 |
Histomorphometrical analysis of the effects of the bisphosphonate alendronate on bone loss caused by experimental periodontitis in monkeys.
Topics: Alendronate; Alveolar Bone Loss; Animals; Bone Density; Diphosphonates; Macaca fascicularis; Mandibu | 1994 |
Local delivery of an amino bisphosphonate prevents the resorptive phase of alveolar bone following mucoperiosteal flap surgery in rats.
Topics: Administration, Topical; Alendronate; Alveolar Bone Loss; Alveolar Process; Animals; Bone Diseases; | 1997 |